What Is Intellia Therapeutics, Inc. (NTLA) Worth in 2026?
According to the CirclFi Deep Alpha Valuation Engine, Intellia Therapeutics, Inc.'s intrinsic value is estimated at $5.44, suggesting the stock is overvalued at its current price of $13.02. With 8 out of 9 models flagging downside (-58.2% average return), the market may be pricing in unsustainable growth. The most optimistic model, PWERM, places fair value at $16.28 (+25.0%), while ML-RIV — the most conservative — estimates $0.55 (-95.8%). This +120.8% gap reflects genuine analytical uncertainty about Intellia Therapeutics, Inc.'s intrinsic worth.
What Do the Models Say About NTLA?
9 of 13 models are currently active for NTLA. Of these, 1 model suggests upside while 8 models suggest overvaluation. The Bayesian DCF estimates NTLA's intrinsic value at $3.52, implying -72.9% downside from the current price. See which stocks rank higher →
How Does NTLA Rank in In Vitro & In Vivo Diagnostic Substances?
Among 17 In Vitro & In Vivo Diagnostic Substances stocks, NTLA ranks #6 by Quality of Company score. CirclFi's QOC score of 6.2/10 evaluates 32 fundamental signals. A score of 6.2 indicates above-average quality.
Intellia Therapeutics, Inc. operates in a competitive landscape where fundamental quality metrics are key differentiators for long-term value creation.
Is NTLA a Value Trap?
CirclFi's Value Trap algorithm assigns NTLA a score of 39/100 (LOW). This indicates low risk. The financial profile does not exhibit typical value trap warning signs. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →
Multi-Model Methodology
9 of 13 models are active for Intellia Therapeutics, Inc.. Moderate coverage provides meaningful perspective. Each model applies a fundamentally different valuation philosophy. See the complete methodology →
According to the CirclFi 32-factor quality framework, Intellia Therapeutics, Inc.'s fundamental quality profile registers 6.2/10. This respectable score captures the company's profitability depth, growth consistency, balance sheet resilience, and shareholder return track record.
The gap between the most bullish and bearish model spans +120.8% — demonstrating why single-model analysis is dangerous. Browse all stocks with 13-model coverage →
Data Sources & Confidence
Every NTLA valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →
Across NTLA's 9 active models, average confidence is 20%. Lower confidence may reflect limited history or high volatility.
CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →
Buy with Gumroad